Advertisement

Topics

Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140

09:46 EST 9 Nov 2018 | Speciality Pharma Journal

HAMPTON, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) presented interim data today from the Phase 1 dose-escalation study of CDX-1140, a fully human agonist anti-CD40 antibody. CD40, expressed on dendritic cells and other antigen presenting cells, has long been an important target for immunotherapy, as it plays a critical role in …

Original Article: Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140

NEXT ARTICLE

More From BioPortfolio on "Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...